<DOC>
	<DOCNO>NCT01417897</DOCNO>
	<brief_summary>The plan HERMES study investigate compare effect Insulin Glulisine , Insulin Aspart regular human insulin postprandial nitrotyrosine concentration several clinical laboratory marker postprandial endothelial cell function , sub-clinical inflammation cardiovascular risk patient type 2 DM . The primary parameter study postprandial change nitrotyrosine concentration , biomarker oxidative stress . As vascular data Insulin Glulisine vs. Insulin Aspart miss , possible calculate sample size statistical power . Therefore goal HERMES-Pilot-Study generate preliminary data statistical consideration estimation probability success HERMES .</brief_summary>
	<brief_title>Human Insulin Analogs : Evaluation Inflammatory mRNA Expression Macrophages Endothelial Function Short-acting Insulin - HERMES Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Short-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes mellitus Stable BOT ( basal oral therapy ) Insulin Glargine + ≥ 2 OHA ( oral hypoglycemic agent except TZD ) minimum three month enter study HbA1c ≤ 8.5 % Age 30 75 year inclusively Body mass index ≤ 40 kg/m2 Patient consent his/her family physician inform trial participation Type 1 diabetes mellitus Unspecific infection inflammation ( hsCRP &gt; 10mg/L POC test ) Use thiazolidinediones within last 3 month prior study start Retinopathy , hepatic renal dysfunction clinically relevant major disease History drug alcohol abuse within last five year prior screen History hypersensitivity study drug ( component study drug ) drug similar chemical structure History severe multiple allergy Treatment investigational drug within 3 month prior screen Progressive fatal disease hepatic ( ALAT and/or ASAT &gt; 3 time normal reference range ) , renal ( creatinine &gt; 1.3 mg/dl woman &gt; 1.6 mg/dl men ) , neurological , psychiatric and/or hematological disease judge investigator Pregnant lactate woman Sexually active woman childbearing potential consistently correctly practice birth control implant , injectables , combine oral contraceptive , hormonal intrauterine device ( IUDs ) , sexual abstinence vasectomize partner Lack compliance similar reason , accord investigator , preclude satisfactory participation study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>